Ignite Creation Date:
2024-05-05 @ 11:46 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00127829
Status:
COMPLETED
Last Update Posted:
2009-04-23
First Post:
2005-08-05
Brief Title:
Study Evaluating Gefitinib IRESSA in Subjects With Solid Malignancies That Are Locally Advanced Recurrent or Metastatic
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Phase I Open-Label Dose Escalation Study Evaluating High-Dose Gefitinib IRESSA on Weekly and Twice Weekly Schedules in Subjects With Solid Malignancies That Are Locally Advanced Recurrent or Metastatic
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AGUS
Brief Summary:
This study will determine the safety profile and maximum tolerated dose MTD of orally administered gefitinib on a weekly and twice weekly schedule
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None